Skip to Content

Cancer Genomics

The cancer genomics and molecular profiling group aims to advance the understanding of changes in the activity of human genes that contribute at the molecular level to the tumor progression and resistance to drugs with an ultimate goal of improving clinical outcomes. The toolbox includes digital gene expression profiling by state-of-the-art techniques NanoString and RNAseq, as well as mutation analysis by whole exome and whole genome next generation sequencing (the image is a visualization of millions of sequence reads produced in parallel), microarrays, and multicolor FISH. The IACS is capable of performing molecular characterization of thousands of samples per year, in addition to retaining the necessary flexibility to rapidly address actual challenges of the institute’s drug validation pipeline.       

The cancer genomics and molecular profiling group is led by Alexei Protopopov, Ph.D.

Newsletter

MD Anderson Hightlights

External Media Coverage

Join our Team

Contact Us

Institute for Applied Cancer Science
MD Anderson Cancer Center
1901 East Road
Houston TX 77054
Tel: 713-745-2600

For questions concerning collaborations or partnerships, please contact:

Eric Devroe
Executive Director of Strategic Alliances
EJDevroe@mdanderson.org

We need your help

Philanthropic support will provide IACS several critical advantages that will ultimately benefit cancer patients by providing them with novel treatments in a shorter timeframe. If you’re interested in advancing this transformative venture, please donate through the myGiving site.


© 2013 The University of Texas MD Anderson Cancer Center